Global Human Microbiome Market - Analysis By Product (Probiotics, Prebiotics, Medical Food, Others), By Disease, Application, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)

Global Human Microbiome Market - Analysis By Product (Probiotics, Prebiotics, Medical Food, Others), By Disease, Application, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)

Executive Summary

The Human Microbiome market was valued at USD 351.81 million in the year 2018. Over the recent years, human microbiome market has been witnessing considerable growth on the back of rising incidences of diabetes, growing geriatric population, and continuous research and development conducted by pharmaceutical manufacturers and academia. In addition, growing sedentary lifestyle, increasing incidence of diabetes and chronic diseases globally have contributed to the growth rate of Human Microbiome market. These factors are anticipated to provide higher momentum to the market growth in the forecast period. Further, the increasing collaboration in the industry between market players and academia to generate data and treatment for the diseases including gut related problems which can be tackled with the help of microbiota, facilitating the growth of the market.

Among the Product type in the human microbiome industry (probiotics, prebiotics, medical foods, and other), Probiotics holds the highest market share in the Human Microbiome Market owing to its proven benefits in gut microbiota and health of the patient.

The North America Human Microbiome Market will continue to be the largest market throughout the forecast period, majorly driven by favourable government reimbursement policies in addition to high healthcare awareness. Countries such as India, China, Brazil are a lucrative market for Human Microbiome Market.



Scope of the Report

  • The report analyses the Human Microbiome market at global, regional and country levels.
  • The report analyses the Human Microbiome Market by Product (Probiotics, Prebiotics, Medical Food and Others).
  • The report assesses the Human Microbiome market by Disease (Obesity, Diabetes, Cancer, Autoimmune Disorder, Gastrointestinal Disorder and Others).
  • The report evaluates the Human Microbiome market By Application (Therapeutic and Diagnostics).
  • The Global Human Microbiome Market has been analysed By Region (North America, Europe, Asia Pacific, ROW) and By Country (U.S., Canada, Mexico, U.K., Germany, France, India, China, Japan, South Korea).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by product, disease and application. Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include OptiBiotix Health Plc, Metabiomics, OSEL Inc., PureTech Health, 4D Pharma, Synlogic Inc., BaseClear BV, Rebiotix Inc, Ritter Pharmaceuticals, Assembly Bioscience Inc.
  • The report presents the analysis of human microbiome market for the historical period of 2014-2018 and the forecast period of 2019-2024.
Key Target Audience
  • Food and Beverage Companies
  • Human Microbiome Vendors
  • Consulting and Advisory Firms
  • Government and Policy Makers
  • Investment Banks and Equity Firms
  • Regulatory Authorities


1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
2.1 APAC region to witness augmented growth in the forecast period.
2.2 Invest in Research and Development activities
3. Global Human Microbiome Market: Product Outlook
4. Global Human Microbiome Market: Sizing and Forecast
4.1 Market Size, By Value, Year 2014-2024
Table 1: Global Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 2: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
Table 3: Number of New Cases of Cancer, In 2018, By Region, (% of Total)
Table 4: Number of New Cases of Cancer, 2018, By Type, (% of Total)
Table 5: Global Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
Table 6: Global Prevalence of Diabetes Type II, 2014-2017 (In Millions)
Table 7: Prevalence of Diagnosed Autoimmune Diseases, In 2018, By Selected Countries, (% of Total)
Table 8: Prevalence of diagnosed gastrointestinal conditions, By Select Countries, 2017 (In %)
Table 9: Global Aged Population (Above 65), 2013-2017 (% of total)
Table 10: Global Aged Population(Above 65), By Country, 2017 (% of total)
Table A: Association of the Gut Microbiome with Therapeutic Effects of Drugs
Table 11: Number of microbiome modulators in active development, by year, 2012–17
Table 12: Global Microbiome, No. of active drugs in market
Table 13: Obese Population, By Country, 2017 (In Millions)
5. Global Human Microbiome Market Segmentation By Product (By Value)
5.1 Competitive Scenario of Global Human Microbiome Market – By Product
Table 14: Inner Pie: Segmental Analysis By Product: Year 2018, Outer Pie: Segmental Analysis By Product: Year 2024
5.2 Probiotics – Market Size and Forecast (2019-2024)
Table 15: Global Human Microbiome Market- By Probiotic, By Value (USD Million), 2014-2024
5.3 Prebiotics - Market Size and Forecast (2019-2024)
Table 16: Global Human Microbiome Market- By Prebiotic, By Value (USD Million), 2014-2024
5.4 Medical Foods - Market Size and Forecast (2019-2024)
Table 17: Global Human Microbiome Market- By Medical Food, By Value (USD Million), 2014-2024
5.5 Others - Market Size and Forecast (2019-2024)
Table 18: Global Human Microbiome Market- By Others, By Value (USD Million), 2014-2024
6. Global Human Microbiome Market Segmentation By Disease (By Value)
6.1 Competitive Scenario of Global Human Microbiome – By Disease
Table 19: Inner Pie: Segmental Analysis By Disease: Year 2018, Outer Pie: Segmental Analysis By Disease: Year 2024
6.2 Obesity – Market Size and Forecast (2019-2024)
Table 20: Global Human Microbiome Market- By Obesity, By Value (USD Million), 2014-2024
6.3 Diabetes Type II - Market Size and Forecast (2019-2024)
Table 21: Inner Global Human Microbiome Market- By Diabetes Type II, By Value (USD Million), 2014-2024
6.4 Autoimmune Disorder – Market Size and Forecast (2019-2024)
Table 22: Global Human Microbiome Market- By Autoimmune Disorder, By Value (USD Million), 2014-2024
6.5 Cancer – Market Size and Forecast (2019-2024)
Table 23: Global Human Microbiome Market- By Cancer, By Value (USD Million), 2014-2024
6.6 Gastrointestinal Disorder – Market Size and Forecast (2019-2024)
Table 24: Global Human Microbiome Market- By Gastrointestinal Disorder, By Value (USD Million), 2014-2024
6.7 Others – Market Size and Forecast (2019-2024)
Table 25: Global Human Microbiome Market- By Others, By Value (USD Million), 2014-2024
7. Global Human Microbiome Market Segmentation By Application (By Value)
7.1 Competitive Scenario of Global Human Microbiome: By Application
Table 26: Inner Pie: Segmental Analysis By Application: Year 2018, Outer Pie: Segmental Analysis By Application: Year 2024
7.2 Therapeutics – Market Size and Forecast (2019-2024)
Table 27: Global Human Microbiome Market- By Therapeutic, By Value (USD Million), 2014-2024
7.3 Diagnostics - Market Size and Forecast (2019-2024)
Table 28: Global Human Microbiome Market- By Diagnostics, By Value (USD Million), 2014-2024
8. Global Human Microbiome Market: Regional Analysis
8.1 Competitive Scenario of Global Human Microbiome: By Region
Table 29: Global Market Scenario, By Region (USD Million)
Table 30: Inner Pie: Segmental Analysis By Region: Year 2018, Outer Pie: Segmental Analysis By Region: Year 2024
9. North America Human Microbiome Market: Segmentation By Products, Disease, Application (2019-2024)
9.1 North America Human Microbiome Market: Size and Forecast (2019-2024)
Table 31: North America Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 32: United States health care expenditure per capita,2013-2016(USD)
Table 33: Canada health care expenditure per capita,2013-2016(USD)
Table 34: North America Healthcare Cost Per Capita, 2017 (USD)
Table 35: North America population aged 65 and above, 2013-2017 (% of total)
Table 36: North America Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
Table 37: North America Prevalence of Diabetes Type II, 2014-2017 (In Millions)
Table B: Prominent Human Microbiome companies operating in Americas Market
9.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other)
Table 38: North America Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
9.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others)
Table 39: North America Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
9.4 Market Segmentation By Application (Therapeutics & Diagnostics)
Table 40: North America Human Microbiome- By Application, By Value (USD Million), 2014-2024
9.5 North America Human Microbiome Market: Country Analysis
9.6 Market Opportunity Chart of North America Human Microbiome Market - By Country, By Value (Year-2024)
Table 41: Market Opportunity Chart of North America Human Microbiome Market - By Country, By Value (Year-2024)
9.7 Competitive Scenario of North America Human Microbiome: By Country
Table 42: Inner Pie: Segmental Analysis By Country: Year 2018, Outer Pie: Segmental Analysis By Country: Year 2024
9.8 United States Human Microbiome Market: Size and Forecast (2019-2024)
Table 43: United States Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 44: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Table 45: U.S., Population ages 65 and above, 2013-2017 (% of total)
Table 46: U.S., Percentage of IBD patients that received select treatments as of 2017 (in %)
Table 47: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)
Table 48: United States Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
Table 49: United States Prevalence of Diabetes Type II, 2014-2017 (In Millions)
9.9 United States Human Microbiome Market Segmentation By Product, Disease, Application
Table 50: United States Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 51: United States Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 52: United States Human Microbiome- By Application, By Value (USD Million), 2014-2024
9.10 Canada Human Microbiome Market: Size and Forecast (2019-2024)
Table 53: Canada Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 54: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
Table 55: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Table 56: Canada, Population ages 65 and above, 2012-2017 (% of total)
Table 57: Canada Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
Table 58: Canada Prevalence of Diabetes Type II, 2014-2017 (In Millions)
Table 59: Prevalence of Diabetics in Canada, (% of Total Population) 2015 & 2045E
Table 60: Estimated Prevalence of Pre-Diabetics in Canada, (% of Total Population) 2015 & 2045E
Table 61: Overweight and Obese Population in Canada, 2015-2017 (% of total)
9.11 Canada Human Microbiome Market Segmentation By Product, Disease, Application
Table 62: Canada Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 63: Canada Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 64: Canada Human Microbiome- By Application, By Value (USD Million), 2014-2024
9.12 Mexico Human Microbiome Market: Size and Forecast (2019-2024)
Table 65: Mexico Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 66: Mexico Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
Table 67: Mexico Prevalence of Diabetes Type II, 2014-2017 (In Millions)
9.13 Mexico Human Microbiome Market Segmentation By Products, Disease, Application
Table 68: Mexico Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 69: Mexico Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 70: Mexico Human Microbiome- By Application, By Value (USD Million), 2014-2024
10. Europe Human Microbiome Market: Segmentation By Product, Disease, Application (2019-2024)
10.1 Europe Human Microbiome Market: Size and Forecast (2019-2024)
Table 71: Europe Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 72: European Country Population Aged 65 and Above, 2012-2017 (% of Total)
Table 73: European Union, Population ages 65 and above, 2013-2017 (% of total)
Table 74: Prevalence of Diabetes (Age 18+), 2017 & 2045E (In Million)
Table 75: Diabetes Prevalence (% of population ages 20 to 79), By Select Country, 2017
Table 76: Europe Health Expenditure, By Select Country, 2016 (% of GDP)
Table 77: Europe Population ages 65 years and above (% of total population), 2013-17
Table 78: Europe Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
Table 79: Europe Prevalence of Diabetes Type II, 2014-2017 (In Millions)
Table 80: Per Capita Health Expenditure, By Select Country, 2017 (USD)
Table C: Prominent Human Microbiome companies operating in Europe Market
10.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other)
Table 81: Europe Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
10.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others)
Table 82: Europe Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
10.4 Market Segmentation By Application (Therapeutics & Diagnostics)
Table 83: Europe Human Microbiome- By Application, By Value (USD Million), 2014-2024
10.5 Europe Human Microbiome Market: Country Analysis
10.6 Market Opportunity Chart of Europe Human Microbiome Market - By Country, By Value (Year-2024)
Table 84: Market Opportunity Chart of Human Microbiome Market - By Country, By Value (Year-2024)
10.7 Competitive Scenario of Europe Human Microbiome: By Country
Table 85: Inner Pie: Segmental Analysis By Country: Year 2018, Outer Pie: Segmental Analysis By Country: Year 2024
10.8 United Kingdom Human Microbiome Market: Size and Forecast (2019-2024)
Table 86: United Kingdom Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 87: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)
Table 88: U.K, Population Ages 65 and Above (% of total), 2012-2017
Table 89: UK, Prevalence of Cancer, 2018, (% of Total)
Table 90: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Table 91: U.K, Cause of Death, Percentage Change Between 2007-2017
Table 92: United Kingdom Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
Table 93: United Kingdom Prevalence of Diabetes Type II, 2014-2017 (In Millions)
10.9 United Kingdom Human Microbiome Market Segmentation By Product, Disease, Application
Table 94: United Kingdom Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 95: United Kingdom Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 96: United Kingdom Human Microbiome- By Application, By Value (USD Million), 2014-2024
10.10 Germany Human Microbiome Market: Size and Forecast (2019-2024)
Table 97: Germany Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 98: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Table 99: Germany, Population ages 65 and above, 2012-2017 (% total)
Table 100: Germany Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
Table 101: Germany Prevalence of Diabetes Type II, 2014-2017 (In Millions)
10.11 Germany Human Microbiome Market Segmentation By Product, Disease, Application
Table 102: Germany Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 103: Germany Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 104: Germany Human Microbiome- By Application, By Value (USD Million), 2014-2024
10.12 France Human Microbiome Market: Size and Forecast (2019-2024)
Table 105: France Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 106: France, Health Expenditure, (% of GDP), 2012-2015 (USD)
Table 107: France, Population Ages 65 and Above (% of total), 2012-2017
Table 108: France, Spending on Healthcare, 2015 & 2040$, (USD Per Person)
Table 109: France Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
Table 110: France Prevalence of Diabetes Type II, 2014-2017 (In Millions)
10.13 France Human Microbiome Market Segmentation By Products, Disease, Application
Table 111: France Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 112: France Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 113: France Human Microbiome- By Application, By Value (USD Million), 2014-2024
10.14 Rest of the Europe Human Microbiome Market: Size and Forecast (2019-2024)
Table 114: Rest of The Europe Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
10.15 Rest of the Europe Human Microbiome Market Segmentation By Products, Disease, Application
Table 115: Rest of The Europe Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 116: Rest of The Europe Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 117: Rest of The Europe Human Microbiome- By Application, By Value (USD Million), 2014-2024
11. Asia Pacific Human Microbiome Market: Segmentation By Products, Disease, Application (2019-2024)
11.1 Asia Pacific Human Microbiome Market: Size and Forecast (2019-2024)
Table 118: APAC Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 119: Population ages 65 and above, APAC Region, By Select Countries, 2017 (% of total)
Table 120: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
Table 121: Diabetes Prevalence (% of population ages 20 to 79), By Selected Country, 2017
Table 122: Obesity Rate, By Selected Country, 2017 (In Percentage)
Table D: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
Table 123: Asia Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
Table 124: Asia Prevalence of Diabetes Type II, 2014-2017 (In Millions)
Table 125: Obesity Rate, By Select Country, 2017 (In Percentage)
11.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other)
Table 126: APAC Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
11.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others)
Table 127: APAC Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
11.4 Market Segmentation By Application (Therapeutics & Diagnostics)
Table 128: APAC Human Microbiome- By Application, By Value (USD Million), 2014-2024
11.5 Asia Pacific Human Microbiome Market: Country Analysis
11.6 Market Opportunity Chart of Asia Pacific Human Microbiome Market - By Country, By Value (Year-2024)
Table 129: Market Opportunity Chart of APAC Human Microbiome Market - By Country, By Value (Year-2024)
11.7 Competitive Scenario of Asia Pacific Human Microbiome: By Country
Table 130: Inner Pie: Segmental Analysis By Country: Year 2018, Outer Pie: Segmental Analysis By Country: Year 2024
11.8 China Human Microbiome Market: Size and Forecast (2019-2024)
Table 131: China Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 132: China, Population Ages 65 and Above, 2012-2017 (% of total)
Table 133: China, Cancer Incidences ( in Million)
Table 134: China Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
Table 135: China Prevalence of Diabetes Type II, 2014-2017 (In Millions)
11.9 China Human Microbiome Market Segmentation By Product, Disease, Application
Table 136: China Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 137: China Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 138: China Human Microbiome- By Application, By Value (USD Million), 2014-2024
11.10 India Human Microbiome Market: Size and Forecast (2019-2024)
Table 139: India Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 140: India, Population Ages 65 and Above, 2013-2017
Table 141: India Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
Table 142: India Prevalence of Diabetes Type II, 2014-2017 (In Millions)
Table 143: India, Diseases Outlook & India, Medical Industry Outlook
11.11 India Human Microbiome Market Segmentation By Product, Disease, Application
Table 144: India Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 145: India Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 146: India Human Microbiome- By Application, By Value (USD Million), 2014-2024
11.12 Japan Human Microbiome Market: Size and Forecast (2019-2024)
Table 147: Japan Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 148: Japan, GDP Growth Per Year, 2015-2019F (In %)
Table 149: Japan Healthcare Expenditure Outlook (%)
Table 150: Japan, Population ages 65 and above, 2012-2016 (% of total)
Table 151: Japan Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
Table 152: Japan Prevalence of Diabetes Type II, 2014-2017 (In Millions)
11.13 Japan Human Microbiome Market Segmentation By Products, Disease, Application
Table 153: Japan Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 154: Japan Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 155: Japan Human Microbiome- By Application, By Value (USD Million), 2014-2024
11.14 South Korea Human Microbiome Market: Size and Forecast (2019-2024)
Table 156: South Korea Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 157: South Korea Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
Table 158: South Korea Prevalence of Diabetes Type II, 2014-2017 (In Millions)
11.15 South Korea Human Microbiome Market Segmentation By Products, Disease, Application
Table 159: South Korea Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 160: South Korea Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 161: South Korea Human Microbiome- By Application, By Value (USD Million), 2014-2024
11.16 Rest of the Asia Pacific Human Microbiome Market: Size and Forecast (2019-2024)
Table 162: Rest of the APAC Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
11.17 Rest of the Asia Pacific Human Microbiome Market Segmentation By Products, Disease, Application
Table 163: Rest of the APAC Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
Table 164: Rest of the APAC Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
Table 165: Rest of the APAC Human Microbiome- By Application, By Value (USD Million), 2014-2024
12. Rest of the World Human Microbiome Market: Segmentation By Products, Disease, Application (2019-2024)
12.1 Rest of the World Human Microbiome Market: Size and Forecast (2019-2024)
Table 166: Rest of the World Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
Table 167: Latin America and Caribbean, Population ages 65 and above (% of total)
Table 168: Middle East and North Africa, Population ages 65 and above (% of total)
Table 169: Cancer Prevalence in Latin America & Caribbean , (% of total), 2018
Table 170: Population ages 65 and above, By Select Country, 2018 (% of total)
Table 171: Population ages 60 or above, By Select Country, 2050 (% of total)
12.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other)
Table 172: ROW Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
12.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others)
Table 173: ROW Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
12.4 Market Segmentation By Application (Therapeutics & Diagnostics)
Table 174: ROW Human Microbiome- By Application, By Value (USD Million), 2014-2024
13. Global Human Microbiome Market Dynamics
13.1 Global Human Microbiome Market Drivers
13.2 Global Human Microbiome Market Restraints
13.3 Global Human Microbiome Market Trends
14. Market Attractiveness and Strategic Analysis
14.1 Market Attractiveness
14.1.1 Market Attractiveness Chart of Global Human Microbiome Market - By Products (Year 2024)
Table 175: Market Attractiveness Chart of Global Human Microbiome Market - By Products (Year-2024)
14.1.2 Market Attractiveness Chart of Global Human Microbiome Market - By Disease (Year 2024)
Table 176: Market Attractiveness Chart of Global Human Microbiome Market - By Disease (Year-2024)
14.1.3 Market Attractiveness Chart of Global Human Microbiome Market - By Application (Year-2024)
Table 177: Market Attractiveness Chart of Global Human Microbiome Market - By Application (Year-2024)
14.1.4 Market Attractiveness Chart of Global Human Microbiome Market - By Region, By Value, (Year-2024)
Table 178: Market Attractiveness Chart of Global Human Microbiome Market - By Region, By Value, (Year-2024)
Table E: List Of Pipeline Products
Table F: Microbiome Licensing Deals Between Big Pharma & Biotech (2014-2019)
14.2 Strategic Analysis
14.2.1 Key Developments in Human Microbiome Market
14.2.3 Human Microbiome PIPELINE Projects
15. Competitive Landscape
15.1 Microbiome Licensing Deals Between Big Pharma and Biotech
15.2 Market Share Analysis
15.3 SWOT Analysis
15.4 Porter’s Five Force Analysis
16. Company Profiles (Business Description, Financial Analysis, Business Strategy)
16.1 OptiBiotix Health Plc
Table 179: OptiBiotix Health Plc Annual Revenue (USD Th.), Year 2015-2018
Table 180: OptiBiotix Health Plc Net Profit/Loss (USD Th.), Year 2014-2018
16.2 Metabiomics
16.3 OSEL Inc.
16.4 PureTech Health
Table 181: PureTech Health Annual Revenue (USD Million), Year 2014-2018
Table 182: PureTech Health Net Profit/Loss (USD Million), Year 2014-2018
16.5 4D Pharma
Table 183: 4D Pharma Investment in R&D (USD Th.), 2014-2018
Table 184: 4D Pharma Net Loss (USD Th.) 2014-2018
16.6 Synlogic Inc.
Table 185: Synlogic Inc. Investment in R&D (USD Th.), 2014-2018
Table 186: Synlogic Inc. Net Loss (USD Th.) 2014-2018
Table 187: Synlogic Inc. Revenue (USD Th.), 2017-2018
16.7 BaseClear BV
16.8 Rebiotix Inc
16.9 Ritter Pharmaceuticals
Table 188: Ritter Pharmaceuticals Investment in R&D (USD Th.) 2014-2018
Table 189: Ritter Pharmaceuticals Net Loss (USD Th.) 2014-2018
16.10 Assembly Bioscience Inc.
Table 190: Assembly Bioscience Inc. Investment in R&D (USD Th.) 2014-2018
Table 191: Assembly Bioscience Inc. Net Loss (USD Th.) 2014-2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook